77484-99-2

Usage

Uses

Used in Pharmaceutical Research:
METHYL 4H-FURO[3,2-B]PYRROLE-5-CARBOXYLATE is used as a building block for the synthesis of complex molecules, particularly in the development of new drugs. Its unique structure and biological activities make it a valuable intermediate for pharmaceutical applications.
Used in Organic Synthesis:
In the field of organic synthesis, METHYL 4H-FURO[3,2-B]PYRROLE-5-CARBOXYLATE is utilized as a key component in the creation of various complex organic compounds, contributing to the advancement of chemical research and development.
Used in Agrochemical Development:
METHYL 4H-FURO[3,2-B]PYRROLE-5-CARBOXYLATE is employed as a precursor in the development of new agrochemicals, leveraging its biological activities to enhance crop protection and management.
Used in Materials Science:
METHYL 4H-FURO[3,2-B]PYRROLE-5-CARBOXYLATE is used in materials science for its potential applications in the development of new materials, taking advantage of its unique structural properties and versatility.
Used in Methodology Development for Chemical Synthesis:
METHYL 4H-FURO[3,2-B]PYRROLE-5-CARBOXYLATE is utilized in the exploration of new methodologies for chemical synthesis, aiming to improve the efficiency and effectiveness of synthetic processes.

InChI:InChI=1/C8H7NO3/c1-11-8(10)6-4-7-5(9-6)2-3-12-7/h2-4,9H,1H3

Upstream product

• 102244-88-2 β-(2-Furyl)-α-azidoacrylsaeuremethylester 
• 164667-41-8 methyl 2-azido-2-(furan-2-yl)acrylate 
• 98-01-1 furfural 

Downstream Products

• 892398-08-2 4-(2-oxo-2-phenyl-ethyl)-4H-furo[3,2-b]pyrrole-5-carboxylic acid methyl ester 
• 1007388-09-1 methyl 6-bromo-4H-furo[3,2-b]pyrrole-5-carboxylate 
• 892398-11-7 4-(2-oxo-2-phenyl-ethyl)-4H-furo[3,2-b]pyrrole-5-carboxylic acid 
• 67268-37-5 4H-furo[3,2-b]pyrrole-5-carboxylic acid 
• 1146291-70-4 4-(4-chlorobenzyl)-4H-furo[3,2-b]pyrrole-5-carboxylic acid 
• 1263388-08-4 2-methoxyphenyl 4H-furo[3,2-b]pyrrole-5-carboxylate 

Relevant academic research and scientific papers

PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE

The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.

Continuous flow thermolysis of azidoacrylates for the synthesis of heterocycles and pharmaceutical intermediates

An efficient, safe and scalable procedure for the continuous flow thermolysis of azidoacrylates to yield indoles has been developed and was applied to the synthesis of related heterocycles. The scalability of the process was demonstrated in the continuous flow synthesis of a precursor to the DAAO inhibitor 4H-furo[3,2-b]pyrrole-5-carboxylic acid.

PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE

The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D- amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.

Intramolecular C-H amination reactions: Exploitation of the Rh 2(II)-catalyzed decomposition of azidoacrylates

Rhodium(II) perfluorobutyrate-mediated decomposition of vinyl azides provides a new, mild entry into Rh2(II) nitrenoid chemistry. This methodology allows rapid access to a variety of complex, functionalized N-heterocycles in two steps from commercially available starting materials. Copyright

Bicyclic pyrrole derivatives as MCP-1 inhibitors

A pharmaceutical composition comprising a compound of formula (I): or a pharmaceutically acceptable salt, ester or amide thereof, which is an inhibitor of monocyte chemoattractant protein-1 and wherein A and B together form an optionally substituted 5-member aromatic ring which includes at least one heteroatom; R1is an optionally substituted aryl or heteroaryl ring; R2is selected from a range of organic groups including carboxy, and R3is hydrogen, or a range of organic groups; in combination with a pharmaceutically acceptable carrier. Certain compounds of formula (I) are novel and these form a further aspect of the invention.